

**AMENDMENTS TO THE CLAIMS**

113. (Currently Amended) A method for eliciting or enhancing an immune response to HER-2/neu protein in a warm-blooded animal, the method comprising administering to said warm-blooded animal a composition comprising a polypeptide ~~protein~~ comprising [a contiguous] the amino acid sequence of having SEQ ID NO:6, where said SEQ ID NO:6 is administered in an amount effective to elicit or enhance the immune response to HER-2/Neu, and wherein the immune response to HER-2/neu is elicited or enhanced in said animal.
114. (Canceled) The method of claim 113, wherein the composition is administered in the form of a vaccine.
115. (Canceled).
116. (Currently Amended) A method for eliciting or enhancing an immune response to HER-2/neu protein in a warm-blooded animal, the method comprising administering to said warm-blooded animal a composition comprising [a protein] polypeptide comprising [a contiguous] the amino acid sequence of having SEQ ID NO:7, where said SEQ ID NO:7 is administered in an amount effective to elicit or enhance the immune response to Her-2/Neu, and wherein the immune response to HER-2/neu is elicited or enhanced in said animal.
117. (currently amended) The method of claim 113, wherein said polypeptide ~~protein~~ is lipidated.
118. (Previously presented) The method of claim 113, wherein the composition comprises a physiologically acceptable carrier or diluent.
119. (Previously presented) The method of claim 118, wherein the composition comprises an oil-in-water emulsion.

120. (Previously presented) The method of claim 119, wherein the composition comprises tocopherol.
121. (Previously presented) The method of claim 113, wherein the composition comprises an immunostimulatory substance.
122. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
123. (Previously presented) The method of claim 121, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
124. (Previously presented) The method of claim 123, wherein the composition comprises tocopherol.
125. (Previously presented) The method of claim 113, wherein the composition comprises a CpG-containing oligonucleotide.
- 126-144. (Canceled).
145. (Canceled) The method of claim 116, wherein the composition is administered in the form of a vaccine.
146. (Currently amended) The method of claim 116, wherein said polypeptide ~~protein~~ is lipidated.
147. (Previously presented) The method of claim 116, wherein the composition comprises a physiologically acceptable carrier or diluent.

148. (Previously presented) The method of claim 147, wherein the composition comprises an oil-in-water emulsion.
149. (Previously presented) The method of claim 148, wherein the composition comprises tocopherol.
150. (Previously presented) The method of claim 116, wherein the composition comprises an immunostimulatory substance.
151. (Previously presented) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL, QS21, or a combination of 3D-MPL and QS21.
152. (Previously presented) The method of claim 150, wherein the composition comprises an immunostimulatory substance comprising 3D-MPL and QS21 in an oil-in-water emulsion.
153. (Previously presented) The method of claim 152, wherein the composition comprises tocopherol.
154. (Previously presented) The method of claim 116, wherein the composition comprises a CpG-containing oligonucleotide.
155. (previously presented). The method of claim 113 where said warm-blooded animal is a human.
156. (previously presented) The method of claim 116, where said warm-blooded animal is a human.